NASDAQ:ALRN
Aileron Therapeutics, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.aileronrx.comipo date
Jun 29, 2017
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus